Improving how the immune system recognizes and fights cancer using targeted nanoparticles
Official title: Enhancing Tumor Antigen Presentation with Complement Targeted Nanoparticles
Funded at University of Alaska Anchorage · NIH-10360368 · Data updated 2026-11-12
This study is exploring a new way to help your immune system fight cancer by using special tiny bubbles that deliver cancer-related proteins to immune cells, making them work better together to attack tumors.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alaska Anchorage NIH-funded |
| Lab location | 1 site (Anchorage, United States) |
| Project start | August 1, 2018 |
| Project end | April 30, 2026 |
| Funding year | 2022 |
| Award (this year) | $441,796 |
| NIH project number | 2R15CA227740-02 |
| Project ID | NIH-10360368 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who may benefit from improved immunotherapy options.
✕Less likely to help
Patients with non-solid tumors or those who are not eligible for immunotherapy may not receive benefits from this research.
What this research studies
This research focuses on enhancing the immune response against cancer by improving the way tumor antigens are presented to immune cells. It utilizes a novel liposome delivery system, known as C3-liposomes, which targets various antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. By encapsulating tumor antigens and immune-activating compounds within these liposomes, the goal is to stimulate a stronger immune response that can effectively eliminate tumors. The research aims to identify the best combinations of antigens and immune stimulators to optimize this process.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that enhance the body's ability to fight tumors.
How similar studies have gone: Preliminary results from similar approaches using targeted nanoparticles have shown promise in animal models, indicating potential for success in human applications.
Where this research is happening
-
University of Alaska Anchorage
Anchorage, United States Active
Researchers
- Principal investigator: Kullberg, Max Peter — University of Alaska Anchorage
- Study coordinator: Kullberg, Max Peter
Related research
Other NIH-funded projects on the same topics.
-
How wildfires and stress during pregnancy affect birth outcomes in Alaskan women
This study is looking at how exposure to wildfire smoke and other stressors might affect the chances of preterm birth in pregnant women in Alaska, especially among American Indian and Alaska Native communities, to help improve healthcare for those who need it most.
-
Investigating copper toxicity and its effects on the brain in a mouse model of Wilson Disease
This study is looking at Wilson Disease, a condition that causes too much copper to build up in the body, and it's testing new treatments, like zinc salts, to see if they can help reduce harmful effects on the brain and liver while being safer than current medications.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.